Northern Trust
GTBP icon

Northern Trust’s GT Biopharma GTBP Stock Holding History

Northern Trust’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,078
Closed -$8.25K – 4447
2023
Q4 		$8.25K Hold
1,078
– – ﹤0.01% 4430
2023
Q3 		$7.8K Hold
1,078
– – ﹤0.01% 4413
2023
Q2 		$10.1K Hold
1,078
– – ﹤0.01% 4477
2023
Q1 		$17.8K Sell
1,078
-21
-2% -$481 ﹤0.01% 4469
2022
Q4 		$29.2K Hold
1,099
– – ﹤0.01% 4402
2022
Q3 		$58K Sell
1,099
-211
-16% -$16.1K ﹤0.01% 4286
2022
Q2 		$118K Sell
1,310
-4,150
-76% -$315K ﹤0.01% 4104
2022
Q1 		$472K Sell
5,460
-222
-4% -$19.6K ﹤0.01% 3762
2021
Q4 		$520K Buy
5,682
+112
+2% +$16.8K ﹤0.01% 3793
2021
Q3 		$1.13M Sell
5,570
-1,945
-26% -$585K ﹤0.01% 3513
2021
Q2 		$3.5M Buy
7,515
+6,369
+556% +$2.65M ﹤0.01% 3052
2021
Q1 		$235K Buy
+1,146
New +$200K ﹤0.01% 4056

Other funds holding GTBP

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Northern Trust's GTBP Position: Q1 2024 in Review

Northern Trust sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 1,078 shares — an estimated $8.25K sold.

Northern Trust first reported a position in GTBP in Q1 2021 and held it in 12 quarters. The position peaked at $3.5M in Q2 2021. 17 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

  • Northern Trust reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
  • Northern Trust sold 1,078 GT Biopharma shares in Q1 2024, an estimated $8.25K.
  • Northern Trust first reported a position in GT Biopharma in Q1 2021 and held it in 12 quarters.
  • Northern Trust's GT Biopharma position peaked at $3.5M in Q2 2021.
  • 17 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on Northern Trust's 13F filing for Q1 2024, filed 14 May 2024.